ReviewCurrent opinion in organ transplantation2011
Posttransplant lymphoproliferative disease following liver transplantation.
Review in Current opinion in organ transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 100 citations in OpenAlex.
- Machine Learning-Based Evaluation of Combined EBV and CMV Serostatus as Predictors of Post-Transplant Lymphoproliferative Disorder.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Ocular Involvement in Post-Transplantation Lymphoproliferative Disorder: A Rare Case with Rituximab Hypersensitivity.The American journal of case reports · 2025Article
- The value of contrast-enhance ultrasound in the diagnosis of hepatic post-transplant lymphoproliferative disease: Four case reports.Intractable & rare diseases research · 2024Article
- A case of early multifocal posttransplant lymphoproliferative disease in an adult after liver transplantation and literature analysis.Quantitative imaging in medicine and surgery · 2024Article
- The role of natural killer T cells in liver transplantation.Frontiers in cell and developmental biology · 2023Review
- Bickerstaff's brainstem encephalitis mimicking herpetic encephalomyelitis in a liver transplant patient with anti-GQ1b antibodies.BMJ case reports · 2022Article
- Long-Term Survival and Kidney Function in Pediatric Patients Following Liver Transplantation: A 15-Year Retrospective Cohort Study.Children (Basel, Switzerland) · 2022Article
- Hepatic Encephalopathy: From Metabolic to Neurodegenerative.Neurochemical research · 2021Review
- Post-Liver Transplant Lymphoproliferative Disorder Presenting as Biliary Stricture.ACG case reports journal · 2021Article
- Post-transplant indolent T cell lymphoproliferative disorder in living donor liver transplantation: a case report.Surgical case reports · 2020Article
- Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.Journal of Korean medical science · 2020Article
- Double-hit monomorphic B-cell lymphoma after liver transplantation.BMJ case reports · 2020Article
- Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease.Clinical journal of gastroenterology · 2019Article
- Donor-derived Viral Infections in Liver Transplantation.Transplantation · 2018Review
- Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.Oncology letters · 2018Article
- Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient.ACG case reports journal · 2018Article
- Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.Oncotarget · 2017Article
- The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification.PloS one · 2017Article
- Infectious Complications After Liver Transplantation.Gastroenterology & hepatology · 2015Article
- Current developments in pediatric liver transplantation.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewDespite contemporary immunosuppressive regimens, posttransplant lymphoproliferative disease (PTLD) remains a major complication after liver transplantation. This review highlights advances in the understanding of the pathophysiology, diagnosis, and management of PTLD in liver transplant recipients. RECENT
findingsThe spectrum of PTLD after liver transplant ranges from polymorphic lymphoproliferation to high-grade monoclonal lymphoma and is usually related to outgrowth of lymphocytes infected with Epstein-Barr virus (EBV). Risk factors for PTLD include EBV-seronegativity of the recipient, young age, intensity of immunosuppression, and the first year posttransplant. Measurement of EBV load by quantitative polymerase chain reaction assays is an important aid in the surveillance and diagnosis of PTLD although the specificity for PTLD is only about 50% (specificity for EBV is ∼100%). In patients diagnosed with PTLD, management options include reduction of immunosuppression, rituximab, combination chemotherapy, and adoptive immunotherapy. Outcomes have improved because rituximab has been incorporated into treatment regimens, and immunotherapy approaches show promise. SUMMARY: PTLD is a significant complication after liver transplantation, particularly in children. Advances in early detection approaches have aided in the diagnosis and management of PTLD, but further research to identify better predictive biomarkers is needed to improve risk-based treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.